Trial Profile
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer: A Phase I Study With a Maximum Tolerated Dose Expansion Cohort
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Everolimus (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 03 May 2021 Status changed from active, no longer recruiting to completed.
- 27 Apr 2021 Planned End Date changed from 1 Apr 2021 to 1 May 2021.
- 27 Apr 2021 Planned primary completion date changed from 1 Apr 2021 to 1 May 2021.